Clinical Accelerator, a full-service contract research organization, is pleased to announce that it has entered into a collaboration with Reprieve Cardiovascular, LLC for conducting a study aimed at optimally decongesting patients with Acute Decompensated Heart Failure (ADHF). The study will also identify and collect the parameters that can be used to develop the next generation of the Reprieve Cardiovascular System.
A US study showed that 1,000,000 annual admissions of heart failure are caused by fluid retention – a typical clinical feature of ADHF. For such a significant condition, the treatment options remain suboptimal. The leading therapy is administration of furosemide and other diuretics but it has an unreliable impact on fluid loss. The problem is that, although ADHF patients have extra litres of fluid in their body, they may be intravascularly dehydrated. Injecting diuretics however only allows the loss of fluid from these already dehydrated intravasculature. This in turn causes ‘diuretic resistance’, whereby the kidneys attempt to retain the fluid lost after the diuretic in effort to compensate, causing fluid retention to increase and urine output to drop to sometimes even zero. This can eventually result in so much fluid being retained that it builds up in the patients’ lungs, causing pulmonary edema and death. Clearly a change to the current standard of care needs to be made and this study is attempting to do just that.
About Reprieve Cardiovascular, LLC
Reprieve is a pioneering medical device company from Massachusetts, United States, with a focus on improving the care and outcome of patients with Acute Decompensated Heart Failure. Their aim is to provide clinicians with the ability to control patients’ fluid volume with precision which would in turn both improve cardiac care and aid decongestion of ADHF patients.
About Clinical Accelerator
Clinical Accelerator is an independent clinical trial management organisation operating principally in Central and Eastern Europe, Russia, Ukraine and CIS countries. The organisation offers a broad range of clinical trial services together with dedicated patient enrolment support to worldwide clients in the pharmaceutical, biotechnological, nutraceutical and medical device industries. Clinical Accelerator’s model of operation is designed to achieve significant cost savings for its clients and to guarantee compact timelines for patient enrolment with a firm focus on the quality of clinical trial data.
 Costanzo M.R. Agostoni P, Marenzi G. Extracorporeal fluid removal in heart failure patients. Contrib Nephrol 2010;164:173-98. Epub 2010 Apr 20.